BRAF and neoplasm: However, these inhibitors cause paradoxical activation of MAPK pathways by mediating RAF‐independent activation of MEK and ERK when used against tumours that are BRAF wild‐type or KIAA1549‐BRAF fused and can cause increased tumour progression and growth.98